Navigation Links
Cellectis bioresearch Makes Genome Engineering Affordable for All Users
Date:2/28/2011

Follow Cellectis on Twitter at www.twitter.com/cellectis.  

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with the IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) TALEN: Transcription Activator-Like Effector Nuclease


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cellectis In-Licenses Induced Pluripotent Stem Cell Technology From iPS Academia Japan
2. Cellectis Publishes Its Financial Statement for the First Half of 2010
3. Cellectis bioresearch Announces Establishment of Subsidiary in the US
4. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
5. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
6. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
7. SAP Makes Life Easier for Patients and More Efficient for Healthcare Providers Through New Technology
8. Pinnaclife Makes it Official With Launch Slated for March 1st
9. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
10. US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
11. Panasonic Makes Investment in Houston-based CardioNexus Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Inc. (NYSE: RMD ) today announced results for ... was $423.0 million, a 10 percent increase compared to the ... a constant currency basis). Net income was $91.2 million, an ... 31, 2013. Diluted earnings per share for the quarter were ...
(Date:1/22/2015)...  Profil Institute for Clinical Research, Inc., a clinical research ... a new textbook,  Translational Research Methods for Diabetes, Obesity ... global scientific publisher. The textbook is the ... in early phase clinical studies of new drugs for ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Allergy Diagnostics Market by Allergen Source, Product & by ... their offering. The global allergy diagnostics market ... to grow at a CAGR of 12.67%, to reach $2,230.72 ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Terumo Heart, Inc. announced,today that it ... the European,Association of Cardio-Thoracic Surgeons (EACTS) meeting ... ) (Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO ) ... Trial results for the DuraHeart(TM),Left Ventricular Assist ...
... analysis reported,at the American Society for Bone and ... decreased clinical fracture risk by 50% over,three years ... women with,osteoporosis who had suffered a previous hip ... evaluated the combined incidence,of vertebral and nonvertebral clinical ...
Cached Medicine Technology:Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 3Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 4
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Men with prostate cancer treated with a specialized ... (IMRT) have fewer gastrointestinal complications compared to patients ... to a study presented November 1, 2010, at ... for Radiation Oncology (ASTRO). , "With ...
... invasive bladder cancer allows 67 percent of people to be ... This compares to 54 percent of people who receive radiation ... presented at the plenary session, November 1, 2010, at the ... (ASTRO). , "The trial shows that this treatment offers improved ...
... Discovery Fund (LSDF) today announced a $5 million grant ... and commercialize new drugs to treat a variety of ... and the sales of drugs in the marketplace, an ... a new non-profit initiative to advance the life sciences ...
... Serena Gordon HealthDay Reporter , MONDAY, Oct. 25 ... sleep-starved parents: Most infants will start sleeping through the night ... take a little longer, however, is for the baby,s eight ... according to the study. "The most rapid changes in ...
... genes A team of researchers, led ... Kingdom, has shed new light on genetic factors that ... of pregnancy, specifically recurrent miscarriage, preeclampsia, and fetal growth ... a successful pregnancy is the invasion of the lining ...
... - Researchers have identified an important signaling pathway that, ... cancer. In their study, researchers at The ... Houston found that blocking the Notch pathway in mice ... a series of pre-clinical studies were reported Sunday in ...
Cached Medicine News:Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9Health News:Researchers find pathway that drives spread of pediatric bone cancer in preclinical studies 2
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
The cordless Simon Dermatome with rechargeable battery is used to harvest split-thickness skin grafts and for debridement....
... quality and innovation has resulted in one ... Model C is an air dermatome especially ... in burn care surgery. The Model C ... same dedication to quality, durability and reliability ...
Needle holder, delicate, curved without lock...
Medicine Products: